ANXA1 and lung cancer: In lung cancer, up-regulation of HSP90β is associated with the worst prognosis and poor survival [29,30]; therefore, it has been proposed as a possible risk biomarker along with annexin A1 [31]; even with lung adenocarcinoma, increased levels of HSP90β have been associated to poor survival and metastasis [32,33].